CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

tak-117

Small moleculeexperimental

Clinical trial activity

9 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2011 (NCT01449370)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • ink-1117
  • ink-1117
  • mln1117
  • mln1117
  • mln-1117
  • mln-1117
  • tak-117
  • tak-117

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03193853Phase 2Jul 5, 2017Baylor University, Takeda
NCT03154294Phase 1Jul 1, 2017Avera Cancer Institute, Avera Health
NCT02724020Phase 2Jun 30, 2016Millennium Pharmaceuticals, Takeda
NCT02725268Phase 2Apr 1, 2016European Network of Individualized Treatment in Endometrial Cancer, European Network of Translational Research in Ovarian Cancer, Millennium Pharmaceuticals
NCT02625259Phase 1Feb 1, 2016Millennium Pharmaceuticals, Takeda
NCT02551055Phase 1Sep 1, 2015Millennium Pharmaceuticals, Takeda
NCT02393209Phase 1/Phase 2 (Phase 2)Jun 1, 2015Millennium Pharmaceuticals
NCT01899053Phase 1Jul 1, 2013Millennium Pharmaceuticals
NCT01449370Phase 1Oct 1, 2011Millennium Pharmaceuticals
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Millennium PharmaceuticalsFor profit7722011
TakedaFor profit4022015
Avera Cancer InstituteAcademic/Hospital1012017
Avera HealthAcademic/Hospital1112017
Baylor UniversityAcademic/Hospital1112017
European Network of Individualized Treatment in Endometrial CancerAcademic/Hospital1012016
European Network of Translational Research in Ovarian CancerAcademic/Hospital1012016
7 organizations
Page 1 / 1